Compare FedEx Corporation (FDX) vs Cassava Sciences Inc (FLNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FedEx Corporation vs Cassava Sciences Inc — how do they compare? FedEx Corporation trades at $316.19 (market cap $74.78B), while Cassava Sciences Inc trades at $1.08 (market cap $53.14M). The key difference: FedEx Corporation is far larger — about 1407.2× Cassava Sciences Inc's market cap, and FedEx Corporation pays a 1.56% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FDX | FLNA | |
|---|---|---|
Market Cap | $74.78B | $53.14M |
Sector | Industrials | Health |
52-Week High | $338.75 | $4.64 |
52-Week Low | $174.81 | $1.09 |
Enterprise Value | $104.42B | -$33.43M |
Dividend Yield | 1.56% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FedEx (FDX) trades at $316.24, up 0.82% on the day, with a bearish technical signal despite recent earnings beats. The company shows steady revenue near $88B and net income of $4.09B in 2025, supported by a P/E of 16.9 and strong analyst consensus. Recent developments include the sale of FedEx Supply Chain for $1.4B and a $4.15B debt tender offer, enhancing financial flexibility.
The outlook is mixed: cost-cutting initiatives and strategic divestitures provide upside, but competitive pressures from Amazon and soft shipping demand pose risks. With 57% of analysts rating it Buy and a $360.27 price target, the stock offers potential appreciation if margin recovery aligns with guidance, though execution remains key.
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About FedEx Corporation
FedEx pioneered overnight delivery in 1973 and remains the world's largest express package provider. In its fiscal 2020 (ended May 2020), FedEx derived 51% of revenue from its express division, 33% from ground, and 10% from freight, its asset-based less-than-truckload shipping segment. The remainder comes from other services, including FedEx Office, which provides document production/shipping, and FedEx Logistics, which provides global forwarding. FedEx acquired Dutch parcel delivery firm TNT Express in 2016. TNT was previously the fourth-largest global parcel delivery provider.
Read more on FDX →About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →
